Abstract: The optically pure isomer of nitrendipine having anti-hypertensive activity, is a potent anti-hypertensive drug for reducing blood pressure in individuals without the undesirable side effects associated with administration of a racemic mixture of nitrendipine. A method is disclosed utilizing an optically pure isomer of nitrendipine for treating hypertension while reducing undesirable side effects associated with nitrendipine.

Abstract: This invention relates to a composition for use in the treatment of iodine deficiency diseases such as fibrocystic dysplasia of the breast, breast cancer, endometriosis and premenstrual syndrome. The composition may also be used for the prophylaxis of breast cancer. More particularly, this invention relates to a composition for the treatment of iodine deficiency diseases, the composition comprising a solution of elemental iodine (I.sub.2) which may also be referred to as metallic iodine or iodine metal. The elemental iodine is soluble in water which leaves it thermodynamically free. The term "aqueous iodine" may also be used to refer to such an aqueous solution.

Abstract: The administration of tin protoporphyrin, tin mesoporphyrin or tin diiododeuteroporphyrin to mammals, notably humans, increases the rate at which heme is excreted by mammals, and is useful for treatment of body tissue injury associated with hemorrhage in the body.

Abstract: The invention relates to amine-containing porphyrin derivatives. Theporphyrins can be used as photosensitizers which are useful as therapeutic agents. Also described are methods for preparing conjugates in which a porphyrin derivative is covalently attached to an antibody or antibody fragment. In vivo therapeutic methods utilizing the conjugates are also desired.

Abstract: Physically and chemically stable insecticidal preparation in the form of aqueous emulsion or suspension is provided wherein active ingredients which are oily or solid and hardly soluble or insoluble in water are mixed in water with nonionic surfactants having an HLB value of 11 or less and thickeners.

Abstract: The novel antitumor antibiotic designated herein as BU-3420T is produced by fermentation of Micromonospora chersina strain M956-1 (ATCC 53710). BU-3420T and its triacetate derivative possess antibacterial and antifungal activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.

Abstract: Oral or parenteral administration of thyroid hormone T.sub.4 (from 0.5 to 2 .mu.g/100 g of body weight) stimulates, normalizes dopaminergic innervation in the corpus striatum (striate body), and restores neurochemical compensation following denervation of selective brain areas, thereby increasing neuronal plasticity.

Abstract: A method is provided for treating Parkinson's Disease by administering to a subject an effective symptom-alleviating amount of a compound selected from the group consisting of phytic acid, phytate salt, an isomer or hydrolysate of phytic acid or phytate salt, or a mixture of any combination thereof. The preferred method of administration is by oral dosages of about 1/8 to 1/2 grams/kilogram bodyweight per day.

Abstract: Inflammatory bowel disease and other leukotriene-mediated inflammation of the intestinal mucosa are treated therapeutically by the oral, rectal or parenteral administration of racemic-6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyloxy]-3,4-d ihydro-2H-1-benzopyran-2-carboxylic acid, or a salt, lower alkyl ester or enantiomer thereof.

Abstract: Compositions useful for carrying physiologically active agents such as therapeutic agents through skin and other body membranes comprising the agent and an effective, non-toxic amount of a compound having the structural formula ##STR1## wherein R' is H or a lower alkyl group, m is 3, N is 6-11 and R is --CH.sub.3.

Abstract: The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation end products of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

Abstract: A preparation for treatment of addiction to alcohol, containing a carbamic acid ester having the general formula I ##STR1## wherein X is --CH.sub.3 or --CH.sub.2 CH.sub.3, R and R.sub.1 which may be the same or different, are hydrogen, C.sub.1-5 alkyl or a group of the formula ##STR2## wherein n is 0, 1 or 2, and R.sub.2, R.sub.3 and R.sub.4 are H, OH, OCH.sub.3, CH.sub.3, NO.sub.2 or halogen, and wherein R and R.sub.1 together with the nitrogen atom can form a saturated ring system having 4-6 atoms selected among C, N, O or S, and wherein A is sulphur or oxygen.

Abstract: The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

Abstract: This invention relates to a treatment for the improvement of regeneration of injured striated muscles, the key-feature of which is the application of n-butylamine, in natural or ionic form or in buffered solution, as effective substance.

Abstract: A treatment regimen for cancers having cells which are susceptible to an interleukin-2 activated natural killer cell mediated anti-cancer effect, the method comprises administering to a patient an effective amount of a combination of interleukin 2 and flavone-8-acetic acid. The treatment regimen is particularly effective in the treatment of renal carcinoma. Synergistic pharmaceutical compositions are also provided. effective in the treatment of renal carcinoma. Synergistic pharmaceutical compositions are also provided.

Abstract: .alpha.-[10-oxy-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-4-ylidene]-carboxyli c acids, or physiologically-hydrolysable and -acceptable esters or pharmaceutically acceptable salts thereof are useful for effecting monokine inhibition, in particular interleukin-1 release or secretion inhibition, as a therapeutic means other than anti-inflammatory or anti-pyretic means.

Abstract: A method for treatment of a hepatobiliary disease which comprises administering, to a subject in need of such treatment, a 15-ketoprostaglandin compound in an amount effective in treatment of the hepatobiliary disease.

Abstract: A pharmaceutical composition for treating inflammatory diseases, comprising (A) an effective amount of hyaluronic acid or its salt, and (B) an effective amount of an anti-inflammatory agent. The composition exhibits a synergistic therapeutic effect on inflammations and is useful for treating inflammatory diseases, particularly diseases of joint with inflammation.

Abstract: A method for treating epilepsy in humans which comprises administering stiripentol to a patient under antiepileptic treatment with usual drugs in order to alleviate or prevent side effects. The invention also provides an antiepileptic composition comprising stiripentol.

Abstract: 2-aryl substituted N-acetyl tryptamines are utilized as antidepressant agents.